Willemien V. D.
- Country
- The Netherlands
- Department
- Gynaecologic Oncology
Research Overview
- Comparison of Body Surface Area-Based Versus Concentration-Based Dosing of Cisplatin in Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
- Phase III Trial on Dose-Dense Carboplatin-Paclitaxel Regimen in Poor Prognostic Ovarian Cancer with Incomplete Debulking Surgery
- Synergistic Effects of PARP Inhibition with Cisplatin and Hyperthermia in Cytoreductive Surgery and HIPEC for Ovarian, Fallopian Tube, and Extraovarian Cancer
Data & Insights
Has run more than one trial at 1 of 59 partner sites.
Specializations
Gynecologic Oncology
This investigator specializes in treating advanced ovarian cancer, with particular focus on FIGO stage III epithelial ovarian cancer. Their research encompasses innovative therapeutic approaches for gynecologic malignancies including fallopian tube cancer and peritoneal cancer.
- High-grade serous carcinoma
- Extraovarian malignancies
- Advanced-stage gynecologic cancers
Surgical Oncology
The investigator focuses on cytoreductive surgery techniques, particularly in the context of advanced ovarian cancer treatment. Their expertise includes both primary and interval surgical interventions aimed at achieving optimal tumor reduction.
- Primary cytoreductive procedures
- Interval debulking surgery
- Minimally residual disease approaches
Therapeutic Innovation
Their research explores advanced treatment modalities including hyperthermic intraperitoneal chemotherapy (HIPEC) and its optimization. The investigator studies various dosing approaches and combination therapies including PARP inhibition with cisplatin under hyperthermic conditions.
- BSA-based treatment protocols
- Concentration-based therapeutic approaches
- Multimodal treatment strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.